Please assess the completion status of the following clinical trial:

Trial Title: ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 12 years of age~* Diagnosed with Acute Hepatic Porphyria (Acute Intermittent Porphyria, Hereditary Corproporhyria, Variegate Porphyria, aminolevulinic acid (ALA) dehydratase deficient porphyria)~* Elevated urinary or plasma porphobilinogen (PBG) or ALA values within the past year,~* Have active disease, with at least 2 documented porphyria attacks within the last 6 months~* Willing to discontinue or not initiate the use of prophylactic hemin throughout the study.~* Women of child bearing potential must have a negative serum pregnancy test, not be nursing, and use acceptable contraception~Exclusion Criteria:~* Clinically significant abnormal laboratory results~* Anticipated liver transplantation~* History of multiple drug allergies or intolerance to subcutaneous injections~* Active HIV, hepatitis C virus, or hepatitis B virus infection(s)~* History of recurrent pancreatitis

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Givosiran/Givosiran (Type: EXPERIMENTAL): Givosiran 2.5 mg/kg administered subcutaneously (SC), monthly (QM), for 6 months during the 6-Month Double-blind (DB) Period, followed by givosiran 2.5 mg/kg or 1.25 mg/kg SC, QM for 29 months during the Open-label Extension (OLE) Period.
- Placebo/Givosiran (Type: PLACEBO_COMPARATOR): Matching placebo (normal saline \[0.9% NaCl\]) was administered SC, QM, for 6 months during the 6-Month DB Period, followed by givosiran 2.5 mg/kg or 1.25 mg/kg SC, QM for 29 months during the OLE period.

Based on this trial design, predict the completion outcome and termination type (if applicable).